KHRNF: AI 评分 59/100 — AI 分析 (4月 2026)

Khiron Life Sciences Corp. operates as an integrated medical cannabis company in Latin America and Europe, focusing on the cultivation, production, and distribution of medical cannabis products. The company also operates health centers and develops CBD-based cosmeceutical products.

Key Facts: AI Score: 59/100 Sector: Healthcare

公司概况

概要：

Khiron Life Sciences Corp. is an integrated medical cannabis company operating in Latin America and Europe. It distinguishes itself through its cultivation, production, and distribution of medical cannabis, coupled with a network of health centers and CBD-based cosmeceutical products, positioning it within the evolving global cannabis market.

KHRNF是做什么的？

Khiron Life Sciences Corp., established in 2012 and headquartered in Vancouver, Canada, operates as an integrated medical cannabis company with a focus on Latin America and Europe. The company's business is structured around three segments: Health Services, Medical Cannabis Products, and Wellbeing Products. Khiron cultivates, produces, distributes, and exports tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The company has established a network of health centers and satellite clinics under the ILANS and Zerenia brands, providing medical cannabis consultations and treatments. Additionally, Khiron develops and markets CBD-based cosmeceutical products under the Kuida brand. Its operations include a Zerenia clinic in Medellin, Colombia, and Peru, expanding access to medical cannabis treatments in the region. Khiron aims to establish itself as a leader in the Latin American and European medical cannabis markets by integrating cultivation, production, distribution, and patient care.

KHRNF的投资论点是什么？

Khiron Life Sciences Corp. presents an investment opportunity within the expanding medical cannabis market in Latin America and Europe. The company's integrated business model, encompassing cultivation, production, distribution, and clinic operations, offers potential for revenue diversification and market penetration. A key value driver is the increasing acceptance and legalization of medical cannabis in target markets, which could drive demand for Khiron's products and services. Growth catalysts include expanding the network of Zerenia clinics and developing new CBD-based products. However, potential risks include regulatory uncertainties, competition from other cannabis companies, and the company's current negative profit margin of -258.9%. Investors should monitor the company's ability to achieve profitability and navigate the evolving regulatory landscape.

KHRNF在哪个行业运营？

Khiron Life Sciences Corp. operates in the burgeoning medical cannabis industry, which is experiencing significant growth due to increasing legalization and acceptance of cannabis for medical purposes. The global medical cannabis market is projected to reach billions of dollars in the coming years. Khiron competes with other cannabis companies, including ANTCF (Antibe Therapeutics Inc.), BSPK (Bioscience Properties Inc.), EVIO (EVIO Inc.), GENPF (General Cannabis Corp), and HEMP (HEMP, Inc.), as well as established pharmaceutical companies exploring cannabis-based treatments. Khiron's focus on Latin America and Europe differentiates it from competitors primarily focused on North America.

Drug Manufacturers - Specialty & Generic

Healthcare

KHRNF有哪些增长机遇？

Expansion of Zerenia Clinics: Khiron can expand its network of Zerenia clinics across Latin America and Europe. Each new clinic increases patient access to medical cannabis treatments, driving revenue growth. The medical cannabis market in Latin America is projected to grow significantly, offering a substantial opportunity for Khiron to capture market share through clinic expansion. Timeline: Ongoing.
Development of New CBD Products: Khiron can develop and launch new CBD-based products, including cosmeceuticals and wellness products. The global CBD market is experiencing rapid growth, driven by increasing consumer awareness of the potential health benefits of CBD. This presents a significant opportunity for Khiron to diversify its revenue streams and expand its customer base. Timeline: Ongoing.
Strategic Partnerships: Khiron can form strategic partnerships with pharmaceutical companies, research institutions, and healthcare providers to expand its reach and access new markets. Partnerships can provide access to new technologies, distribution channels, and patient populations. This can accelerate Khiron's growth and enhance its competitive position. Timeline: Ongoing.
Regulatory Approvals: Securing regulatory approvals for its medical cannabis products in new markets can drive significant revenue growth for Khiron. As more countries legalize medical cannabis, Khiron can expand its geographic footprint and access new patient populations. This requires navigating complex regulatory processes and demonstrating the safety and efficacy of its products. Timeline: Ongoing.
International Exports: Khiron can increase its exports of medical cannabis products to international markets. The global medical cannabis market is expanding rapidly, creating opportunities for Khiron to supply its products to countries with limited domestic production capacity. This requires establishing international distribution networks and complying with export regulations. Timeline: Ongoing.

Operates in the rapidly growing medical cannabis market in Latin America and Europe.
Integrated business model encompassing cultivation, production, distribution, and clinic operations.
Gross margin of 22.5% indicates potential for profitability with increased scale.
Network of health centers and satellite clinics under the ILANS and Zerenia brands provides a direct channel to patients.
Development of CBD-based cosmeceutical products under the Kuida brand diversifies revenue streams.

KHRNF提供哪些产品和服务？

Cultivates and produces medical cannabis.
Distributes and exports medical cannabis products.
Operates a network of health centers and satellite clinics under the ILANS and Zerenia brands.
Develops CBD-based cosmeceutical products under the Kuida brand name.
Provides medical cannabis consultations and treatments.
Operates Zerenia clinics in Medellin and Peru.

KHRNF如何赚钱？

Cultivation and production of medical cannabis.
Distribution and sale of medical cannabis products through clinics and other channels.
Provision of medical consultations and treatments at Zerenia clinics.
Sale of CBD-based cosmeceutical products.

Patients seeking medical cannabis treatments.
Consumers of CBD-based cosmeceutical products.
Healthcare providers prescribing medical cannabis.
Distributors of medical cannabis products.

Integrated business model encompassing cultivation, production, distribution, and clinic operations.
Established network of health centers and satellite clinics.
Brand recognition in Latin America and Europe.
Expertise in cultivating and producing high-quality medical cannabis.

什么因素可能推动KHRNF股价上涨？

Upcoming: Expansion of Zerenia clinic network to new locations in Latin America and Europe.
Ongoing: Increasing legalization and acceptance of medical cannabis in target markets.
Ongoing: Development and launch of new CBD-based products.
Ongoing: Strategic partnerships with pharmaceutical companies and healthcare providers.
Upcoming: Securing regulatory approvals for medical cannabis products in new countries.

KHRNF的主要风险是什么？

Potential: Regulatory uncertainties and changes in cannabis laws.
Ongoing: Competition from established pharmaceutical companies and other cannabis companies.
Potential: Fluctuations in cannabis prices and supply chain disruptions.
Ongoing: Negative profit margin and limited financial resources.
Potential: Economic downturns and reduced consumer spending.

KHRNF的核心优势是什么？

Integrated business model.
Established presence in Latin America and Europe.
Network of health centers and satellite clinics.
Development of CBD-based cosmeceutical products.

KHRNF的劣势是什么？

Negative profit margin.
Limited financial resources.
Dependence on regulatory approvals.
Intense competition.

KHRNF有哪些机遇？

Expansion of Zerenia clinics.
Development of new CBD products.
Strategic partnerships.
International exports.

KHRNF面临哪些威胁？

Regulatory uncertainties.
Competition from established pharmaceutical companies.
Fluctuations in cannabis prices.
Economic downturns.

KHRNF的竞争对手是谁？

Antibe Therapeutics Inc. — Focuses on pain and inflammation therapeutics. — (ANTCF)
Bioscience Properties Inc. — Real estate investment trust focused on the cannabis industry. — (BSPK)
EVIO Inc. — Provides cannabis testing and analysis services. — (EVIO)
General Cannabis Corp — Operates in various segments of the cannabis industry. — (GENPF)
HEMP, Inc. — Focuses on hemp-based products and solutions. — (HEMP)

Key Metrics

MoonshotScore: 59/100

Company Profile

CEO: Alvaro Francisco Torres
Headquarters: Vancouver, CA
Employees: 310
Founded: 2021

AI Insight

AI analysis pending for KHRNF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Khiron Life Sciences Corp. do?

Khiron Life Sciences Corp. operates as an integrated medical cannabis company in Latin America and Europe. The company cultivates, produces, distributes, and exports medical cannabis products containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Khiron also operates a network of health centers and satellite clinics under the ILANS and Zerenia brands, providing medical cannabis consultations and treatments. Additionally, the company develops and markets CBD-based cosmeceutical products under the Kuida brand, targeting the wellness and beauty markets.

What do analysts say about KHRNF stock?

As of 2026-03-16, formal analyst ratings for KHRNF may be limited due to its OTC listing. However, potential investors should focus on key valuation metrics such as revenue growth, gross margin, and path to profitability. Growth considerations include the expansion of Zerenia clinics, development of new CBD products, and securing regulatory approvals in new markets. Investors should also monitor the company's ability to manage costs and navigate the evolving regulatory landscape.

What are the main risks for KHRNF?

The main risks for Khiron Life Sciences Corp. include regulatory uncertainties surrounding medical cannabis legalization, competition from established pharmaceutical companies and other cannabis companies, and fluctuations in cannabis prices. The company's negative profit margin and limited financial resources also pose significant risks. Additionally, economic downturns and reduced consumer spending could negatively impact demand for Khiron's products and services. Investors should carefully consider these risks before investing in KHRNF.